SG11201901317TA - Anti-pd-l1 antibody - Google Patents

Anti-pd-l1 antibody

Info

Publication number
SG11201901317TA
SG11201901317TA SG11201901317TA SG11201901317TA SG11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA SG 11201901317T A SG11201901317T A SG 11201901317TA
Authority
SG
Singapore
Prior art keywords
antibody
amino acid
acid sequence
seq
rat
Prior art date
Application number
SG11201901317TA
Inventor
Satoru KONNAI
Kazuhiko Ohashi
Shiro Murata
Tomohiro Okagawa
Asami Nishimori
Naoya Maekawa
Yasuhiko Suzuki
Chie Nakajima
Original Assignee
Univ Hokkaido Nat Univ Corp
Fuso Pharm Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hokkaido Nat Univ Corp, Fuso Pharm Ind Ltd filed Critical Univ Hokkaido Nat Univ Corp
Publication of SG11201901317TA publication Critical patent/SG11201901317TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

ANTI-PD-L1 ANTIBODY The present invention provides an anti-PD-L1 antibody capable of repeated administration even to animals other than rat. An anti-PD-L1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLYSENQKDY (SEQ ID NO: 37), CDR2 having the amino acid sequence of WAT and CDR3 having the amino acid sequence of GQYLVYPFT (SEQ ID NO: 38) and the light chain con stant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GYTFTSNF (SEQ ID NO: 39), CDR2 having the amino acid sequence of IYPEYGNT (SEQ ID NO: 40) and CDR3 having the amino acid sequence of ASEEAVISLVY (SEQ ID NO: 41) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-PD-L1 antibody as an active ingredient. A method for preparing the above anti-PD-L1 antibody is also provided. [Fig. 10]
SG11201901317TA 2016-08-15 2017-08-10 Anti-pd-l1 antibody SG11201901317TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016159089 2016-08-15
JP2016159088 2016-08-15
JP2017061454 2017-03-27
JP2017110723 2017-06-05
PCT/JP2017/029055 WO2018034225A1 (en) 2016-08-15 2017-08-10 Anti-pd-l1 antibody

Publications (1)

Publication Number Publication Date
SG11201901317TA true SG11201901317TA (en) 2019-03-28

Family

ID=61196830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901317TA SG11201901317TA (en) 2016-08-15 2017-08-10 Anti-pd-l1 antibody

Country Status (13)

Country Link
US (2) US11312773B2 (en)
EP (1) EP3498838A4 (en)
JP (1) JP6960634B2 (en)
KR (2) KR102569068B1 (en)
CN (1) CN109790533B (en)
AU (1) AU2017313494B2 (en)
BR (1) BR112019002852A2 (en)
CA (1) CA3033896A1 (en)
MX (1) MX2019001896A (en)
PH (1) PH12019500319A1 (en)
RU (1) RU2744862C2 (en)
SG (1) SG11201901317TA (en)
WO (1) WO2018034225A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790533B (en) * 2016-08-15 2023-04-04 国立大学法人北海道大学 anti-PD-L1 antibodies
JP7134417B2 (en) 2017-07-20 2022-09-12 国立大学法人北海道大学 Combinations of PD-1/PD-L1 targeted inhibitors and COX-2 inhibitors
CN111018989B (en) * 2019-12-16 2021-03-23 郑州大学 anti-PD-L1 monoclonal antibody and application thereof in preparation of anti-cancer drugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811102B2 (en) 1989-12-28 1998-10-15 財団法人化学及血清療法研究所 Gene fragment encoding the constant region of feline immunoglobulin gamma chain and mouse x feline chimeric antibody
JP2837240B2 (en) 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 Gene fragment encoding constant region of canine immunoglobulin gamma chain and mouse x dog chimeric antibody
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
AU2006265108C1 (en) * 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
CN104411717A (en) * 2012-01-09 2015-03-11 斯克利普斯研究所 Humanized antibodies with ultralong CDR3S
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9644021B2 (en) * 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
WO2015035173A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
RU2535629C1 (en) 2013-11-12 2014-12-20 Дмитрий Андреевич Соколов Element of construction kit (versions) and construction kit
EP3083685A2 (en) * 2013-12-20 2016-10-26 Intervet International B.V. Canine antibodies with modified ch2-ch3 sequences
EP3201230B1 (en) * 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
CN109790533B (en) * 2016-08-15 2023-04-04 国立大学法人北海道大学 anti-PD-L1 antibodies

Also Published As

Publication number Publication date
WO2018034225A1 (en) 2018-02-22
BR112019002852A2 (en) 2019-06-25
KR20230125085A (en) 2023-08-28
KR102569068B1 (en) 2023-08-21
RU2019105697A3 (en) 2020-09-17
AU2017313494A1 (en) 2019-03-07
CN109790533B (en) 2023-04-04
KR20190039256A (en) 2019-04-10
RU2744862C2 (en) 2021-03-16
CN109790533A (en) 2019-05-21
EP3498838A1 (en) 2019-06-19
US20210277124A1 (en) 2021-09-09
JPWO2018034225A1 (en) 2019-06-20
AU2017313494B2 (en) 2023-09-21
CA3033896A1 (en) 2018-02-22
JP6960634B2 (en) 2021-11-05
US11312773B2 (en) 2022-04-26
RU2019105697A (en) 2020-09-17
PH12019500319A1 (en) 2019-10-21
EP3498838A4 (en) 2020-01-08
US20220227871A1 (en) 2022-07-21
MX2019001896A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019001897A (en) Anti-lag-3 antibody.
CO2019007844A2 (en) Novel human transferrin receptor antibody capable of penetrating the blood brain barrier
MX2018015393A (en) Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof.
PE20161571A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
NZ719036A (en) Anti-pdl1 antibody formulations
AR110321A1 (en) ANTITAU ANTIBODIES AND METHODS OF USE
PE20190970A1 (en) ANTI-CD40 ANTIBODIES AND THEIR USES
EA201892007A1 (en) 3-DESOXY DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS ON ITS BASIS
PE20130393A1 (en) ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION
MX2020008736A (en) B7-h4 antibody formulations.
MX2019001841A (en) Anti-pd-1 antibody.
BR112017009817A2 (en) anti-il-1beta antibodies and methods of use
MX2020009275A (en) Anti-pd-1 antibody compositions.
EA201992570A1 (en) COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION
SG11201901317TA (en) Anti-pd-l1 antibody
EA202092336A1 (en) COMPOUNDS WITH PESTICIDAL EFFECT, COMPOSITIONS AND METHOD FOR PEST CONTROL RELATED TO THEM
MX2021005085A (en) Antibody formulation.
MX2017012615A (en) ANTI-HUMAN Notch 4 ANTIBODY.
MY195550A (en) Antibody Formulation
MX2022013566A (en) Antibody.
PH12019502023A1 (en) Anti-pd-l1 antibody for detecting pd-l1
MX2021009851A (en) Therapeutic antibody formulation.
MX2020005555A (en) Tau peptide immunogen constructs.
MX2021007047A (en) Antibody formulations.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists